Filing Details
- Accession Number:
- 0001209191-22-047760
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-26 19:29:59
- Reporting Period:
- 2022-08-24
- Accepted Time:
- 2022-08-26 19:29:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1599901 | Avidity Biosciences Inc. | RNA | Pharmaceutical Preparations (2834) | 461336960 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1629383 | Sarah Boyce | C/O Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego CA 92121 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-24 | 35,045 | $1.24 | 35,045 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-24 | 35,045 | $22.80 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-08-25 | 14,855 | $1.24 | 14,855 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-25 | 14,855 | $23.07 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-24 | 35,045 | $0.00 | 35,045 | $1.24 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-25 | 14,855 | $0.00 | 14,855 | $1.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,161,870 | 2029-12-17 | No | 4 | M | Direct | |
| 1,147,015 | 2029-12-17 | No | 4 | M | Direct |
Footnotes
- The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.45 to $23.05.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.84 to $23.42.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.
Billionaire Hedge Funds
